|
Evaluation of an OCA2 enhancer variant as a modifier of the phenotype of BAP1-Tumor predisposition syndrome
|
1R21CA219884-01A1
|
$203,471
|
$50,868
|
ABDEL-RAHMAN, MOHAMED
|
OHIO STATE UNIVERSITY
|
|
COG NCTN Network Group Operations Center
|
3U10CA180886-05S1
|
$2,256,906
|
$135,414
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
COG NCTN Solid Malignancy Integrated Translational Science Center
|
5U10CA180884-05
|
$192,024
|
$38,405
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
COG NCTN Network Group Operations Center
|
5U10CA180886-05
|
$20,853,800
|
$1,251,228
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
Network Lead Academic Participating Site: Memorial Sloan-Kettering Cancer Center
|
3U10CA180791-04S1
|
$145,357
|
$4,361
|
AGHAJANIAN, CAROL
|
SLOAN-KETTERING INST CAN RESEARCH
|
|
Network Lead Academic Participating Site: Memorial Sloan-Kettering Cancer Center
|
5U10CA180791-05
|
$922,200
|
$27,666
|
AGHAJANIAN, CAROL
|
SLOAN-KETTERING INST CAN RESEARCH
|
|
ATBC Study
|
ZIA CP010195 03031
|
$738,165
|
$36,908
|
Albanes, Demetrius
|
DCEG (NCI)
|
|
Naional Cancer Institute, Naitonal Clinical Trials Network U10 Lead Academic Site
|
5U10CA180790-05
|
$1,223,634
|
$36,709
|
ALBERTS, STEVEN
|
MAYO CLINIC ROCHESTER
|
|
Biochemical Analysis of Multidrug Resistance-linked Transport Proteins
|
ZIA BC 010030
|
$753,084
|
$37,654
|
Ambudkar, Suresh
|
CCR (NCI)
|
|
Hutchinson Center as Lead Academic Participating Site (U10)
|
5U10CA180828-05
|
$605,293
|
$30,265
|
APPELBAUM, FREDERICK
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Childhood Cancer Survivor Study
|
3U24CA055727-24S1
|
$120,439
|
$12,044
|
ARMSTRONG, GREGORY
|
ST. JUDE CHILDREN'S RESEARCH HOSPITAL
|
|
Childhood Cancer Survivor Study
|
5U24CA055727-24
|
$4,218,764
|
$421,876
|
ARMSTRONG, GREGORY
|
ST. JUDE CHILDREN'S RESEARCH HOSPITAL
|
|
Stanford Cancer Institute
|
3P30CA124435-11S1
|
$248,520
|
$4,970
|
ARTANDI, STEVEN
|
STANFORD UNIVERSITY
|
|
Stanford Cancer Institute
|
3P30CA124435-11S2
|
$171,518
|
$3,430
|
ARTANDI, STEVEN
|
STANFORD UNIVERSITY
|
|
Stanford Cancer Institute
|
5P30CA124435-11
|
$3,334,464
|
$66,689
|
ARTANDI, STEVEN
|
STANFORD UNIVERSITY
|
|
Cancer Center Support Grant - UT Southwestern Medical Center
|
3P30CA142543-09S1
|
$249,371
|
$7,481
|
ARTEAGA, CARLOS
|
UT SOUTHWESTERN MEDICAL CENTER
|
|
Cancer Center Support Grant - UT Southwestern Medical Center
|
5P30CA142543-09
|
$2,480,000
|
$74,400
|
ARTEAGA, CARLOS
|
UT SOUTHWESTERN MEDICAL CENTER
|
|
Cancer Center Support Grant
|
2P30CA082103-19
|
$7,954,381
|
$79,544
|
ASHWORTH, ALAN
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
Cancer Center Support Grant
|
3P30CA082103-19S1
|
$84,000
|
$840
|
ASHWORTH, ALAN
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
Cancer Center Support Grant
|
3P30CA082103-19S2
|
$206,488
|
$2,065
|
ASHWORTH, ALAN
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
Cancer Center Support Grant
|
3P30CA082103-19S3
|
$257,838
|
$2,578
|
ASHWORTH, ALAN
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
Interferon Activated Necroptosis as a New Therapeutic Avenue for Kidney Cancer
|
5R01CA168621-05
|
$379,725
|
$379,725
|
BALACHANDRAN, SIDDHARTH
|
RESEARCH INST OF FOX CHASE CAN CTR
|
|
c-Met-induced Renalase: a novel therapeutic target for renal cancer
|
1R03CA219731-01A1
|
$88,500
|
$88,500
|
BALAN, MURUGABASKAR
|
BOSTON CHILDREN'S HOSPITAL
|
|
A Glycopeptide from Interstitial Cystitis Patients as a Novel Anticancer Lead
|
ZIA BC 011232
|
$314,516
|
$31,452
|
Barchi, Joseph
|
CCR (NCI)
|
|
Anatomic Pathology Residency Program
|
ZIE BC 011384
|
$1,537,925
|
$76,896
|
Barr, Frederic
|
CCR (NCI)
|
|
Regulation of RNA biogenesis and function by RNA modifications
|
ZIA BC 011766
|
$1,075,766
|
$322,730
|
Batista, Pedro
|
CCR (NCI)
|
|
Cancer Center Support Grant
|
3P30CA042014-29S1
|
$125,000
|
$3,750
|
BECKERLE, MARY
|
UNIVERSITY OF UTAH
|
|
Cancer Center Support Grant
|
3P30CA042014-29S2
|
$250,000
|
$7,500
|
BECKERLE, MARY
|
UNIVERSITY OF UTAH
|
|
Cancer Center Support Grant
|
3P30CA042014-29S3
|
$248,625
|
$7,459
|
BECKERLE, MARY
|
UNIVERSITY OF UTAH
|
|
Cancer Center Support Grant
|
3P30CA042014-29S4
|
$114,251
|
$3,428
|
BECKERLE, MARY
|
UNIVERSITY OF UTAH
|
|
Cancer Center Support Grant
|
3P30CA042014-29S5
|
$59,693
|
$1,791
|
BECKERLE, MARY
|
UNIVERSITY OF UTAH
|
|
Cancer Center Support Grant
|
3P30CA042014-29S6
|
$155,422
|
$4,663
|
BECKERLE, MARY
|
UNIVERSITY OF UTAH
|
|
Vanderbilt Network Lead Academic Participating Site for the NCTN
|
5U10CA180847-06
|
$503,410
|
$25,171
|
BERLIN, JORDAN
|
VANDERBILT UNIVERSITY MEDICAL CENTER
|
|
Alliance for Clinical Trials in Oncology Operations Center
|
3U10CA180821-05S1
|
$3,249,644
|
$64,993
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Alliance for Clinical Trials in Oncology Operations Center
|
3U10CA180821-05S2
|
$1,000,000
|
$20,000
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Alliance for Clinical Trials in Oncology Operations Center
|
5U10CA180821-05
|
$8,073,787
|
$161,476
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Development of Natural Product Leads as Anticancer Therapeutics
|
ZIA BC 011470
|
$330,596
|
$82,649
|
Beutler, John
|
CCR (NCI)
|
|
Combating Resistance to Antiangiogenic Therapy in Renal Cell Carcinoma
|
5R01CA196996-04
|
$398,025
|
$398,025
|
BHATT, RUPAL
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Medical Oncology Fellowship Program
|
ZIE BC 010843
|
$3,561,926
|
$356,193
|
Bilusic, Marijo
|
CCR (NCI)
|
|
COMPREHENSIVE CANCER CENTER CORE SUPPORT GRANT
|
3P30CA013148-46S1
|
$52,084
|
$2,604
|
BIRRER, MICHAEL
|
UNIVERSITY OF ALABAMA AT BIRMINGHAM
|
|
COMPREHENSIVE CANCER CENTER CORE SUPPORT GRANT
|
3P30CA013148-46S2
|
$72,961
|
$3,648
|
BIRRER, MICHAEL
|
UNIVERSITY OF ALABAMA AT BIRMINGHAM
|
|
COMPREHENSIVE CANCER CENTER CORE SUPPORT GRANT
|
3P30CA013148-46S3
|
$91,218
|
$4,561
|
BIRRER, MICHAEL
|
UNIVERSITY OF ALABAMA AT BIRMINGHAM
|
|
COMPREHENSIVE CANCER CENTER CORE SUPPORT GRANT
|
3P30CA013148-46S4
|
$45,500
|
$2,275
|
BIRRER, MICHAEL
|
UNIVERSITY OF ALABAMA AT BIRMINGHAM
|
|
COMPREHENSIVE CANCER CENTER CORE SUPPORT GRANT
|
3P30CA013148-46S5
|
$198,945
|
$9,947
|
BIRRER, MICHAEL
|
UNIVERSITY OF ALABAMA AT BIRMINGHAM
|
|
COMPREHENSIVE CANCER CENTER CORE SUPPORT GRANT
|
5P30CA013148-46
|
$5,104,077
|
$255,204
|
BIRRER, MICHAEL
|
UNIVERSITY OF ALABAMA AT BIRMINGHAM
|
|
SWOG Network Group Operations Center of the NCTN
|
3U10CA180888-05S1
|
$670,913
|
$13,418
|
BLANKE, CHARLES
|
OREGON HEALTH & SCIENCE UNIVERSITY
|
|
SWOG Network Group Operations Center of the NCTN
|
5U10CA180888-05
|
$8,625,592
|
$172,512
|
BLANKE, CHARLES
|
OREGON HEALTH & SCIENCE UNIVERSITY
|
|
Hypoxia and Tyrosine Kinase Signaling Integration in Urologic Cancers
|
ZIA BC 011095
|
$213,470
|
$213,470
|
Bottaro, Donald
|
CCR (NCI)
|
|
Oncogenic Met Signaling in Urologic Malignancies
|
ZIA BC 011124
|
$396,445
|
$99,111
|
Bottaro, Donald
|
CCR (NCI)
|
|
Identification of genomic drivers of brain metastases in renal cell carcinoma
|
1R21CA220253-01A1
|
$239,041
|
$239,041
|
BRASTIANOS, PRISCILLA
|
MASSACHUSETTS GENERAL HOSPITAL
|
Total relevant funding to Kidney Disease for this search: $53,289,891
|